未找到相关数据
Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
被引：0
|作者：
Anna Lukačišinová
Helena Skácelová
机构：
[1] State Institute for Drug Control (SIDC),
关键词：
Cost Effectiveness;
Rare Disease;
Antineoplastic Agent;
Market Entry;
Retrospective Observational Study;
D O I：
10.1186/2052-3211-8-S1-O3
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文